Dihydroergotamine and Methylergonovine interaction
Dihydroergotamine and Methylergonovine: both prescribing labels describe an interaction that usually calls for monitoring, a dose change, or spacing the doses.
Usually manageable with monitoring or a dose change. Tell your pharmacist you take both.
What the FDA labels say
From the Dihydroergotamine (Dihydroergotamine Mesylate) label · effective 2026-05-26
Rarely, prolonged daily use of other ergot alkaloid drugs has been associated with cardiac valvular fibrosis.
Other Vasospasm-Related Events Dihydroergotamine Mesylate Injection, USP, like other ergot alkaloids, may cause vasospastic reactions other than coronary artery vasospasm.
From the Methylergonovine (Methylergonovine Maleate) label · effective 2026-04-30
Caution should be exercised when methylergonovine maleate is used concurrently with other vasoconstrictors, ergot alkaloids, or prostaglandins.
…CYP 3A4 Inhibitors (e.g., Macrolide Antibiotics and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g., dihydroergotamine and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities.
Taking more than these two? Interactions stack. Check your whole list at once; it stays in your browser.
Open in the checkerNot medical advice. Interaction Checker quotes FDA label text and NIH fact sheets. Whether an interaction matters for you depends on doses, timing, kidney and liver function, and other conditions. Confirm with a pharmacist or prescriber.